Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index; 22 of the 37 sources its claims cite were checked for support.

Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis

Open access
Xie, Jingqiang, Pu, Chunying, Sun, Mingyue · 2026 · Frontiers in Psychiatry

Abstract

Treatment-resistant depression (TRD) remains a major clinical challenge. Intranasal esketamine, used adjunctively with an oral antidepressant, has been evaluated in randomized trials, but uncertainty persists regarding the magnitude and consistency of benefit, durability, and key harms. This systematic review and meta-analysis included randomized controlled trials comparing intranasal esketamine plus an oral antidepressant versus placebo nasal spray plus the same oral antidepressant in TRD. Acute induction (≈4 weeks) and maintenance randomized-withdrawal phases were analyzed separately. Depression outcomes were assessed primarily using the Montgomery–Åsberg Depression Rating Scale (MADRS), and functional outcomes using the Sheehan Disability Scale (SDS). Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2.0. Random-effects models pooled mean differences (MD) for continuous outcomes, risk ratios (RR) for binary outcomes, and hazard ratios (HR) for relapse prevention. Certainty of evidence was rated using GRADE. From 1,518 records, nine reports representing six unique RCTs (1,836 participants) were included. Four acute induction RCTs (n=937) showed greater symptom reduction at day 28 with esketamine (MADRS MD −2.99, 95% CI −5.10 to −0.89; I²=48.5%). Rapid improvement was evident by day 2 (MD −3.25, 95% CI −4.65 to −1.85). Esketamine increased day-28 response (RR 1.44, 95% CI 1.20–1.74) and remission (RR 1.52, 95% CI 1.20–1.92), corresponding to approximately +154 responders and +106 remitters per 1,000 patients, respectively, based on pooled control risks. Functioning improved (SDS MD −1.70, 95% CI −2.61 to −0.79). Two maintenance randomized-withdrawal RCTs (n=899) demonstrated reduced relapse risk with continued esketamine (HR 0.51, 95% CI 0.42–0.62; I²=0%). In acute induction, esketamine increased any treatment-emergent adverse event (TEAE) (RR 1.37, 95% CI 1.25–1.50) and discontinuation due to adverse events (RR 2.68, 95% CI 1.35–5.29), with notable increases in dissociation (RR 7.33, 95% CI 4.49–11.98) and blood pressure increased events (RR 3.96, 95% CI 2.24–7.01). Maintenance TEAE rates were similar between groups (RR 1.07, 95% CI 0.99–1.17). Intranasal esketamine plus an oral antidepressant provides rapid, modest acute improvement and reduces relapse risk during maintenance among stabilized responders/remitters, but increases acute adverse events, supporting use within supervised care and individualized benefit–risk assessment.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of six RCTs (1,836 participants) found that adjunctive intranasal esketamine plus an oral antidepressant produced rapid but modest acute symptom and functional improvement and reduced relapse risk in stabilized responders/remitters, while increasing acute adverse events. The authors conclude the benefit–harm profile supports use within supervised care and individualized benefit–risk assessment.

Key findings

  • Acute induction (4 RCTs, n=937): esketamine reduced day-28 MADRS change (MD −2.99, 95% CI −5.10 to −0.89; I²=48.5%) and day-2 MADRS change (MD −3.25, 95% CI −4.65 to −1.85), increased response (RR 1.44, 95% CI 1.20–1.74) and remission (RR 1.52, 95% CI 1.20–1.92), improved SDS (MD −1.70, 95% CI −2.61 to −0.79), and increased CGI-I response (RR 1.33, 95% CI 1.16–1.53); absolute increases were +154 responders and +106 remitters per 1,000.
  • Maintenance randomized-withdrawal (2 RCTs, n=899): continued esketamine reduced relapse risk (HR 0.51, 95% CI 0.42–0.62; I²=0%); trial relapse proportions were 25.9% vs 44.0% and 22.1% vs 39.5%, with an absolute risk reduction of 216 per 1,000 using an assumed control relapse risk of 440 per 1,000.
  • Acute safety: any TEAE RR 1.37 (95% CI 1.25–1.50), discontinuation due to AE RR 2.68 (95% CI 1.35–5.29), dissociation RR 7.33 (95% CI 4.49–11.98), and blood pressure increased RR 3.96 (95% CI 2.24–7.01); maintenance any TEAE RR 1.07 (95% CI 0.99–1.17) and any-cause discontinuation RR 0.53 (95% CI 0.38–0.75).
  • GRADE certainty was moderate for MADRS change at day 28, remission, SDS change, relapse prevention, and discontinuation due to AE, and high for response, day-2 MADRS change, dissociation, and blood pressure increased events.

Methods

  • Systematic review and meta-analysis of randomized controlled trials comparing intranasal esketamine plus an oral antidepressant versus placebo nasal spray plus the same oral antidepressant in treatment-resistant depression; acute induction and maintenance randomized-withdrawal phases were analyzed separately.
  • Searched PubMed/MEDLINE, Embase, Cochrane Library, PsycINFO, ClinicalTrials.gov, and WHO ICTRP to December 2025; from 1,518 records, included 9 reports representing 6 unique RCTs (1,836 participants).
  • Two reviewers independently screened, extracted data, and assessed risk of bias with RoB 2.0; random-effects inverse-variance meta-analyses pooled MDs for continuous outcomes, RRs for binary outcomes, and HRs for relapse prevention, with sensitivity analyses, Bayesian meta-analysis, trial sequential analysis, and GRADE.

Limitations

  • Stated in the paper: the protocol was not prospectively registered; several acute trials had “some concerns” due to potential functional unblinding and missing outcome data; some outcomes were informed by only 2–3 trials, limiting precision and publication-bias assessment; backbone-specific efficacy/safety could not be compared; induction trials largely ended at 4 weeks and maintenance used enriched randomized-withdrawal designs; older adults and medically complex populations remain understudied.
  • Evident from the text: only two maintenance trials contributed to relapse prevention, precluding meaningful small-study or publication-bias assessment; the day-28 MADRS prediction interval included the null (−6.59 to +0.60), and the older-adult trial showed a near-null effect with borderline subgroup interaction (p=0.055), indicating possible heterogeneity and uncertain benefit in some settings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2026.1774549

Cites

49 of 50 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Absolute effects per 1,000 participants for key benefit–harm outcomes, derived from pooled control risks and pooled relative effects. Positive values indicate higher event rates with esketamine (beneficial for response/remission; harmful for adverse outcomes), whereas negative values indicate fewer events with esketamine (beneficial for relapse).
Figure 1 Absolute effects per 1,000 participants for key benefit–harm outcomes, derived from pooled control risks and pooled relative effects. Positive values indicate higher event rates with esketamine (beneficial for response/remission; harmful for adverse outcomes), whereas negative values indicate fewer events with esketamine (beneficial for relapse).CC BY · PubMed Central
Figure 2 Revised PRISMA 2020 flow diagram of study identification and selection. Records denote database entries/citations, reports denote full-text articles, and studies denote unique trials. Full-text exclusion reasons are shown in the right-hand panel.
Figure 2 Revised PRISMA 2020 flow diagram of study identification and selection. Records denote database entries/citations, reports denote full-text articles, and studies denote unique trials. Full-text exclusion reasons are shown in the right-hand panel.CC BY · PubMed Central
Figure 3 Risk of bias assessment of included randomized controlled trials using the Cochrane RoB 2.0 tool. Domain-level judgements (D1–D5) and the overall risk-of-bias judgement are shown for each trial (Trials A–F). “Some concerns” in acute trials primarily reflect the potential for functional unblinding and deviations from intended interventions due to distinctive acute subjective effects, and (in selected trials) differential missing outcome data. D1, randomization process; D2, deviations from intended interventions; D3, missing outcome data; D4, measurement of the outcome; D5, selection of the reported result.
Figure 3 Risk of bias assessment of included randomized controlled trials using the Cochrane RoB 2.0 tool. Domain-level judgements (D1–D5) and the overall risk-of-bias judgement are shown for each trial (Trials A–F). “Some concerns” in acute trials primarily reflect the potential for functional unblinding and deviations from intended interventions due to distinctive acute subjective effects, and (in selected trials) differential missing outcome data. D1, randomization process; D2, deviations from intended interventions; D3, missing outcome data; D4, measurement of the outcome; D5, selection of the reported result.CC BY · PubMed Central
Figure 4 Acute induction: MADRS change from baseline to day 28 (random-effects meta-analysis). Random-effects meta-analysis of mean difference (MD) in MADRS change from baseline to day 28 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant in acute induction randomized controlled trials. Negative MD values indicate greater symptom improvement with esketamine. Study weights are from the random-effects model. Heterogeneity statistics (I², τ², Q) and the 95% prediction interval are shown.
Figure 4 Acute induction: MADRS change from baseline to day 28 (random-effects meta-analysis). Random-effects meta-analysis of mean difference (MD) in MADRS change from baseline to day 28 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant in acute induction randomized controlled trials. Negative MD values indicate greater symptom improvement with esketamine. Study weights are from the random-effects model. Heterogeneity statistics (I², τ², Q) and the 95% prediction interval are shown.CC BY · PubMed Central
Figure 5 Acute induction efficacy outcomes: (A) response at day 28, (B) remission at day 28, (C) SDS change at day 28, and (D) MADRS change at day 2. Random-effects meta-analyses of day-28 clinical response (A) and remission (B) comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant. Effect sizes are expressed as risk ratios (RR) with 95% confidence intervals; RR values >1 favor esketamine. Domain-specific heterogeneity statistics are shown beneath each panel, and a 95% prediction interval is provided where heterogeneity is present. Random-effects meta-analysis of mean difference (MD) in Sheehan Disability Scale (SDS) total score change from baseline to day 28 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant in acute induction randomized controlled trials. Negative MD indicates greater improvement in functional impairment with esketamine. Study weights reflect the random-effects model (C). Random-effects meta-analysis of mean difference (MD) in MADRS change from baseline to day 2 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant. Negative MD indicates greater early symptom improvement with esketamine (D).
Figure 5 Acute induction efficacy outcomes: (A) response at day 28, (B) remission at day 28, (C) SDS change at day 28, and (D) MADRS change at day 2. Random-effects meta-analyses of day-28 clinical response (A) and remission (B) comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant. Effect sizes are expressed as risk ratios (RR) with 95% confidence intervals; RR values >1 favor esketamine. Domain-specific heterogeneity statistics are shown beneath each panel, and a 95% prediction interval is provided where heterogeneity is present. Random-effects meta-analysis of mean difference (MD) in Sheehan Disability Scale (SDS) total score change from baseline to day 28 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant in acute induction randomized controlled trials. Negative MD indicates greater improvement in functional impairment with esketamine. Study weights reflect the random-effects model (C). Random-effects meta-analysis of mean difference (MD) in MADRS change from baseline to day 2 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant. Negative MD indicates greater early symptom improvement with esketamine (D).CC BY · PubMed Central
Figure 6 (A) CGI-I responders at day 28 (acute induction) and (B) time to relapse in randomized-withdrawal maintenance trials. Random-effects meta-analysis of CGI-I responder rates at day 28 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant. Effect sizes are expressed as risk ratios (RR) with 95% confidence intervals; RR >1 indicates higher likelihood of clinician-rated global improvement with esketamine (A). Random-effects meta-analysis of hazard ratios (HR) for time to relapse in randomized-withdrawal maintenance trials. HR <1 indicates reduced relapse risk with continued intranasal esketamine plus oral antidepressant compared with switching to placebo nasal spray plus oral antidepressant. Study weights are from the random-effects model; heterogeneity statistics are shown (B).
Figure 6 (A) CGI-I responders at day 28 (acute induction) and (B) time to relapse in randomized-withdrawal maintenance trials. Random-effects meta-analysis of CGI-I responder rates at day 28 comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant. Effect sizes are expressed as risk ratios (RR) with 95% confidence intervals; RR >1 indicates higher likelihood of clinician-rated global improvement with esketamine (A). Random-effects meta-analysis of hazard ratios (HR) for time to relapse in randomized-withdrawal maintenance trials. HR <1 indicates reduced relapse risk with continued intranasal esketamine plus oral antidepressant compared with switching to placebo nasal spray plus oral antidepressant. Study weights are from the random-effects model; heterogeneity statistics are shown (B).CC BY · PubMed Central
Figure 7 Acute induction safety outcomes: any TEAE, discontinuation due to AE, any-cause discontinuation, and serious adverse events (random-effects meta-analyses). Overall safety and tolerability outcomes (acute induction). Panels show random-effects meta-analyses (risk ratios, RR) comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant for: (A) any treatment-emergent adverse event (TEAE), (B) discontinuation due to adverse events, (C) any-cause discontinuation, and (D) serious adverse events. Squares represent study-specific RRs with size proportional to inverse-variance weight; horizontal lines indicate 95% CIs; diamonds indicate pooled effects. The vertical dashed line marks RR = 1.0 (no difference).
Figure 7 Acute induction safety outcomes: any TEAE, discontinuation due to AE, any-cause discontinuation, and serious adverse events (random-effects meta-analyses). Overall safety and tolerability outcomes (acute induction). Panels show random-effects meta-analyses (risk ratios, RR) comparing intranasal esketamine plus oral antidepressant versus placebo nasal spray plus oral antidepressant for: (A) any treatment-emergent adverse event (TEAE), (B) discontinuation due to adverse events, (C) any-cause discontinuation, and (D) serious adverse events. Squares represent study-specific RRs with size proportional to inverse-variance weight; horizontal lines indicate 95% CIs; diamonds indicate pooled effects. The vertical dashed line marks RR = 1.0 (no difference).CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 0 Not valid · 4 Not checked · 102 Own results and interpretations

69 more claims

Create a free account to see all 118 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 32

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 45 references

Research works printed but not linked: 5

  1. 2010, Practice guideline for the treatment of patients with major depressive disorder
  2. 2019, Spravato (esketamine) nasal spray, CIII
  3. HJ, 2013, GRADE handbook for grading quality of evidence and strength of recommendations
  4. H, 2022, Cochrane Handbook for Systematic Reviews of Interventions Version 6.3
  5. 2024, R: A language and environment for statistical computing

Cited by

See all 1

Metadata

Authors
Xie, J., Pu, C., & Sun, M.
Affiliations
Beijing University of Chinese Medicine (CN)
Corresponding author
Xie, Jingqiang
Venue
Frontiers in Psychiatry
Published
2026-07-03
Volume
17
Pages
1774549-1774549
ISSN
1664-0640 (ISSN-L)
OpenAlex
W7167284368
Cited by
1
References
45
Citations by year
2026: 1
FWCI
0.74
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
esketamine, intranasal esketamine, treatment-resistant depression, adjunctive antidepressant therapy, relapse prevention, maintenance therapy, remission, functional disability, treatment-emergent adverse events, NMDA receptor antagonists, risk of bias, quality of evidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fpsyt.2026.1774549
The paper
Xie, J., Pu, C., & Sun, M. (2026). Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2026.1774549

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.